Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease

被引:36
作者
Mooser, V
Helbecque, N
Miklossy, J
Marcovina, SM
Nicod, P
Amouyel, P
机构
[1] Univ Lausanne Hosp, CHU Vaudois, Dept Med, CH-1011 Lausanne, Switzerland
[2] Inst Pasteur, Lille, France
[3] Univ Washington, Seattle, WA 98195 USA
关键词
D O I
10.7326/0003-4819-132-7-200004040-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Apolipoprotein(a) [apo(a)], the distinctive, highly polymorphic glycoprotein of lipoprotein(a), shares a series of common features with apolipoprotein E (apoE), which is implicated in the development of Alzheimer disease. Objective: To determine whether apo(a) is associated with Alzheimer disease. Design: Case-control study. Setting: University hospitals in Europe. Participants: 285 patients with Alzheimer disease and 296 controls. Measurements: Plasma lipoprotein(a) levels, size of the apo(a) isoforms, and apoE and apo(a) genotyping. Results: Among carriers of the apoE epsilon 4 allele, lipoprotein(a) was associated with a progressive, age-dependent increased risk for late-onset Alzheimer disease (odds ratio for patients >80 years of age, 6.0 [95% CI, 1.2 to 30.8]; P < 0.01). Among noncarriers older than 80 years of age, lipoprotein(a) was associated with a reduced risk for Alzheimer disease (odds ratio, 0.4 [CI, 0.2 to 0.9]; P < 0.05). Conclusions: In this convenience sample, lipoprotein(a) was an additional risk factor for late-onset Alzheimer disease in carriers of the apoE epsilon 4 allele. However, lipoprotein(a) may protect against late-onset Alzheimer disease in noncarriers.
引用
收藏
页码:533 / 537
页数:5
相关论文
共 24 条
[11]   HETEROGENEOUS LIPOPROTEIN (A) SIZE ISOFORMS DIFFER BY THEIR INTERACTION WITH THE LOW-DENSITY-LIPOPROTEIN RECEPTOR AND THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA(2)-MACROGLOBULIN RECEPTOR [J].
MARZ, W ;
BECKMANN, A ;
SCHARNAGL, H ;
SIEKMEIER, R ;
MONDORF, U ;
HELD, I ;
SCHNEIDER, W ;
PREISSNER, KT ;
CURTISS, LK ;
GROSS, W ;
HUTTINGER, M .
FEBS LETTERS, 1993, 325 (03) :271-275
[12]   APOE genotype predicts when -: not whether -: one is predisposed to develop Alzheimer disease [J].
Meyer, MR ;
Tschanz, JT ;
Norton, MC ;
Welsh-Bohmer, KA ;
Steffens, DC ;
Wyse, BW ;
Breitner, JCS .
NATURE GENETICS, 1998, 19 (04) :321-322
[13]   The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans [J].
Mooser, V ;
Scheer, D ;
Marcovina, SM ;
Wang, JP ;
Guerra, R ;
Cohen, J ;
Hobbs, HH .
AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (02) :402-417
[14]   SEQUENCE POLYMORPHISMS IN THE APO(A) GENE ASSOCIATED WITH SPECIFIC LEVELS OF LP(A) IN PLASMA [J].
MOOSER, V ;
MANCINI, FP ;
BOPP, S ;
PETHOSCHRAMM, A ;
GUERRA, R ;
BOERWINKLE, E ;
MULLER, HJ ;
HOBBS, HH .
HUMAN MOLECULAR GENETICS, 1995, 4 (02) :173-181
[15]   DIFFERENTIAL-EFFECTS OF APOLIPOPROTEINS E3 AND E4 ON NEURONAL GROWTH IN-VITRO [J].
NATHAN, BP ;
BELLOSTA, S ;
SANAN, DA ;
WEISGRABER, KH ;
MAHLEY, RW ;
PITAS, RE .
SCIENCE, 1994, 264 (5160) :850-852
[16]  
Ramharack R, 1996, J LIPID RES, V37, P2029
[17]   APO(A) ISOFORMS PREDICT RISK FOR CORONARY HEART-DISEASE - A STUDY IN 6 POPULATIONS [J].
SANDHOLZER, C ;
SAHA, N ;
KARK, JD ;
REES, A ;
JAROSS, W ;
DIEPLINGER, H ;
HOPPICHLER, F ;
BOERWINKLE, E ;
UTERMANN, G .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (10) :1214-1226
[18]  
STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004
[19]   Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity - Evidence from a large population of French centenarians [J].
Thillet, J ;
Doucet, C ;
Chapman, J ;
Herbeth, B ;
Cohen, D ;
Faure-Delanef, L .
ATHEROSCLEROSIS, 1998, 136 (02) :389-394
[20]   Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2 [J].
Trommsdorff, M ;
Gotthardt, M ;
Hiesberger, T ;
Shelton, J ;
Stockinger, W ;
Nimpf, J ;
Hammer, RE ;
Richardson, JA ;
Herz, J .
CELL, 1999, 97 (06) :689-701